Collectively, targeting RalA through shRNA potently suppressed the in vivo anticancer activity, while imatinib combined with RalA depletion treatment was effective on the CML CD34+ cell-driven mouse model. Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.